Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

40 mg by mouth (PO) when used with imatinib.

40 mg twice daily when used with nilotinib.

80 mg daily when used with dasatinib or taken alone.

Maximum dose of 400 mg PO once daily.

Maximum dose of 300 mg twice daily.

Maximum dose of 100 mg PO once daily.